Dynamic value assessments in oncology supported by the PACE Continuous Innovation Indicators

Several recently developed frameworks aim to assess the value of cancer treatments, but the most appropriate metrics remain uncertain. We use data from the Patient Access to Cancer care Excellence Continuous Innovation Indicators to examine the relationship between hazard ratios (HRs) from clinical...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2017-10, Vol.13 (25), p.2253-2264
Main Authors: Paddock, Silvia, Goodman, Clifford, Shortenhaus, Scott, Grainger, David, Zummo, Jacqueline, Thomas, Samuel
Format: Article
Language:English
Subjects:
Breast cancer
Cancer therapies
Clinical trials
Clinical Trials as Topic
Cost analysis
Evidence-Based Medicine - methods
Evidence-Based Medicine - standards
hazard ratio
health economics
Humans
Innovations
Medical Oncology - methods
Medical Oncology - standards
Oncology
Outcome Assessment (Health Care) - methods
Patients
Proportional Hazards Models
Quality Indicators, Health Care
Quality of Health Care
Ratios
Regulatory approval
Survival Rate
value assessment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several recently developed frameworks aim to assess the value of cancer treatments, but the most appropriate metrics remain uncertain. We use data from the Patient Access to Cancer care Excellence Continuous Innovation Indicators to examine the relationship between hazard ratios (HRs) from clinical trials and dynamic therapeutic value accumulating over time. Our analysis shows that HRs from initial clinical trials poorly predict the eventual therapeutic value of cancer treatments. Relying strongly on HRs from registration trials to predict the long-term success of treatments leaves a lot of the variance unexplained. The Continuous Innovation Indicators offer a complementing, dynamic method to track the therapeutic value of cancer treatments and continuously update value assessments as additional evidence accumulates.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2017-0241